MIRA INFORM REPORT

 

 

Report No. :

339789

Report Date :

09.09.2015

 

IDENTIFICATION DETAILS

 

Name :

P.T. SURGIKA ALKESINDO

 

 

Registered Office :

Jalan Letjend. Suprapto No. 60, Gedung Indra Sentral Unit G-H, Jakarta Pusat, 10520

 

 

Country :

Indonesia

 

 

Date of Incorporation :

31.01.2000

 

 

Com. Reg. No.:

AHU-AH.01.10-23298

 

 

Legal Form :

Limited Liability Company

 

 

Line of Business :

Trading, Distribution and Supply of Medical Equipment

 

 

No. of Employees :

27

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

US$ 264,000

Status :

Satisfactory

Payment Behaviour :

No Complaints

Litigation :

Clear

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – March 31, 2015

 

Country Name

Previous Rating

(31.12.2014)

Current Rating

(31.03.2015)

Indonesia

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

INDONESIA - ECONOMIC OVERVIEW

 

Indonesia has seen a slowdown in growth since 2012, mostly due to the end of the commodities export boom. During the global financial crisis, Indonesia outperformed its regional neighbors and joined China and India as the only G20 members posting growth. The government has promoted fiscally conservative policies, resulting in a debt-to-GDP ratio of less than 25% and historically low rates of inflation. Fitch and Moody's upgraded Indonesia's credit rating to investment grade in December 2011. Indonesia still struggles with poverty and unemployment, inadequate infrastructure, corruption, a complex regulatory environment, a current account deficit, and unequal resource distribution among regions. President Joko WIDODO - elected in July 2014 - has emphasized maritime and other infrastructure development, and especially increased electric power capacity, since taking office. Fuel subsidies were almost completely removed in early 2015, a move which could help the government increase spending on its development priorities. Indonesia, with the nine other ASEAN members, will continue to move towards participation in the ASEAN Economic Community, though full implementation of economic integration will not be completed by the previously-set deadline of year-end 2015.

 

Source : CIA

 


 

BASIC SEARCH

 

Name of Company :

P.T. SURGIKA ALKESINDO

 

A d d r e s s :

Head Office

Jalan Letjend. Suprapto No. 60

Gedung Indra Sentral Unit G-H

Jakarta Pusat, 10520

Indonesia

Phones             - (62-21) 425 3634 (Hunting)

Fax                   - (62-21) 425 3635

E-mail               - info@surgika.com

Website            - http://www.surgika.com

Building Area    - 2 storey

Office Space    - 120 sq. meters

Region              - Commercial

Status               - Rent

 

Date of Incorporation :

31 January 2000

 

Legal Form :

P.T. (Perseroan Terbatas) or Limited Liability Company

 

Company Reg. No. :

The Ministry of Law and Human Rights

No. AHU-AH.01.10-23298

Dated 23 December 2009

 

Company Status :

National Private Company

 

Permit by the Government Department :

The Department of Finance

NPWP No. 01.899.639.7-073.000

 

The Department of Industry and Trade

TDP No. 09.05.1.51.39559

Dated 6 September 2000

 

Related Company :

P.T. MEGAH ALKESINDO (Trading and Distribution of Medical Equipment)

 

 

 

CAPITAL AND OWNERSHIP

 

Capital Structure :

Authorized Capital                           : Rp. 700,000,000.-

Issued Capital                                 : Rp. 700,000,000.-

Paid up Capital                               : Rp. 700,000,000.-

 

Shareholders/Owners :

a. Mr. Dr. Handy Gunawan                                                - Rp. 280,000,000.-

    Address : Jl. Pademangan II/16, RT. 001 RW. 001

                    Kelurahan Pademangan Barat, Kecamatan

                    Pademangan, Jakarta Utara

                    Indonesia

b. Mrs. Meilani Margaoei                                                  - Rp. 210,000,000.-

    Address : Jl. Pademangan II/16, RT. 001 RW. 001

                    Kelurahan Pademangan Barat, Kecamatan

                    Pademangan, Jakarta Utara

                    Indonesia

c. Mrs. Wanny Surja Prijana                                             - Rp. 210,000,000.-

    Address : Cipinang Jaya LL No. 13, RT. 001 RW. 007

                    Kelurahan Cipinang Besar Selatan, Kecamatan

                    Jatinegara, Jakarta Timur

                    Indonesia

 

 

BUSINESS ACTIVITIES

 

Lines of Business :

Trading, Distribution and Supply of Medical Equipment

 

Production Capacity :

None

 

Total Investment :

None

 

Started Operation :

2000

 

Brand Name :

Surgika Alkesindo

 

Technical Assistance :

None

 

Number of Employee :

27 persons

 

Marketing Area :

Local    - 100%

 

Main Customer :

Hospital and Medical Check Up

 

Market Situation :

Very Competitive

 

Main Competitors :

a. P.T. ATRA WIDIYA AGUNG

b. C.V. GOLDEN STAR

c. P.T. HIDUP SEHAT BERMAKNA

d. P.T. LEBAH LESTARI PRIMA

e. Etc.

 

Business Trend :

Growing

 

 

BANKER, AUDITOR & LITIGATION

 

B a n k e r :

P.T. Bank CENTRAL ASIA Tbk

Jalan Letjend. Suprapto

Cempaka Putih

Jakarta Pusat

Indonesia

 

Auditor :

Internal Auditor

 

Litigation :

No litigation record in our database

 

 

FINANCIAL FIGURE

 

Annual Sales (estimated) :

2012 – Rp. 27.2 billion

2013 – Rp. 28.8 billion

2014 – Rp. 29.6 billion

 

Net Profit (estimated) :

2012 – Rp. 1.7 billion

2013 – Rp. 1.9 billion

2014 – Rp. 2.1 billion

 

Payment Manner :

Average

 

Financial Comments :

Satisfactory

 

 

KEY EXECUTIVES

 

Board of Management :

Director                                          - Mr. Dr. Handy Gunawan

 

Board of Commissioners :

President Commissioner                  - Mrs. Meilani Margoei

Commissioner                                 - Mrs. Wanny Surja Prijana

 

Signatories :

Director (Mr. Dr. Handy Gunawan) which must be approved by Board of Commissioner

 

 

CAPABILITIES

 

Management Capability :

Good

 

Business Morality :

Good

 

Maximum Credit Limit :

US$ 264,000 on 90 days D/A

 

 

OVERALL PERFORMANCE

 

P.T. SURGIKA ALKESINDO (P.T. SA) was established in Jakarta on January 31, 2000 with the authorized capital of Rp. 500,000,000 issued capital of Rp. 200,000,000 fully and paid up. The company was founded by Mr. Dr. Handy Gunawan, his wife Mrs. Meilani Margoei and Mrs. Leony Gunawan, the three are Indonesian business family of Chinese extraction. The company notary deed has been changed a couple of times. In August 2008, the authorized capital was increased to Rp. 700,000,000 entirely issued and paid up. Later in November 2008, the company activity has been shifted from trading and distribution into trading and distribution of medical, services and industry, export import.

 

The latest in December 2009 Mrs. Leony Gunawan pulled out and the whole share sold to Mrs. Wanny Surja Prijana as new shareholder. With this time the composition of its shareholders has been changed to become Mr. Dr. Handy Gunawan (40%) his wife Mrs. Meilani Margoei (30%) and Mrs. Wanny Surja Prijana (30%). The latest revision of notary document was made by Mrs. Hilda Sari Gunawan, SH., was approved by the Ministry of Law and Human Right in its Decision Letter No. AHU-AH.01.10-23298, dated December 23, 2009.

 

P.T. SA has been in operation since 2000 dealing with trading and distribution of medical equipment. In its operation, the company sells various medical equipment such as I.C.U. Equipment ranging from ventilator & pulse oxymeter, suction pump, airway management, Midray China Patient Monitoring System, hospital bed & furniture; Operating Theatre ranging from Suture, electrosurgical products, suction pump, anaesthesia machine, autoclave, sterile gloves, endoscopies instrument, pulse oxymeter, airway management, C02 absorber; OG3 including Richard wolf, endoscopies instrument, etc. P.T. SA is an authorized distributor for ATMOS Medicine Technik GmbH & Co., KG, Germany, LISA Laser Product OHG, HEINE, AMAN Opthalmic Instrument, MEDI Bayreuth, RICHARD WOLF all of Germany; ANMEDIC AB of Sweden; TUTTNAEUR CO., LTD., The Ludlow Company LP, NELLCOR Puritan Bennett, VALLEYLAB, Tyco Healthcare Group LLP all of the USA; Chang Gung Medical Supplier & Equipment Corporation, Mediland Enterprise Corporation both of Taiwan; SHENZHEN Mindray Bio-Medical Electronics Co., Ltd., of People Republic of China; WRP ASIA Pacific Sdn. Bhd., of Malaysia; SUMI Zaklad Torzyw Sztucznych K. Rek, A. Krzanowski, Poland; Chang Gung Medical of Taiwan; and others. The whole merchandise products are sold to various hospitals, health clinics, maternity hospitals in Jakarta, Bandung, Semarang, Yogyakarta, Surabaya, Bali, Medan, Pekanbaru, Padang, Palembang, Lampung, Samarinda, Balikpapan, Banjarmasin, Pontianak, Batam, Manado and other cities in the country. P.T. SA is classified as a medium sized company of its kind in the country of which the operation has been growing in the last three years.

 

Generally, demand for laboratory and medical equipment and various pharmaceutical products had been growing in the last five years. Indonesian pharmaceutical market is still attractive for investment, both for local and foreign investors. This is driven by the growth of national pharmaceutical market that has been rising far above the average growth of the national economy for more than five years. In addition to the aforementioned growth factor, appealing factor of Indonesian pharmaceutical market lays in the lucrative prospect of constantly developing healthcare industry along with stronger purchasing power of the public and stronger awareness of health care, which has contributed to the increasing spending allocated for health sector. The growth of health care infrastructure such as hospitals, pharmacies, community health centers, clinics, private medical practices and drug stores that spread mostly across the region becomes a clear indication that health care facilities become a very important part for the community. This condition is a prospective opportunity for the pharmaceutical industry to develop its business in a larger scale to meet the need of drugs for health care services in all types of available facilities.

 

The growth of the market and the pharmaceutical industry is driven by two main factors, namely the increasing number of drug consumption by the public and the increasing supply of new products launched by manufacturers or principal. The increasing amount of consumption and the addition of new product launched give direct effect on the increasing number of production and supply of the products as a whole. In the lower middle-class society, the increasing consumption occurs due to the opening of public access to health care products and services through health insurance program. This program directly links between unfortunate communities with health care and medical expenses. As for the upper middle class, rising incomes have a significant impact on the change of drug consumption patterns. Self-medication becomes an integral part of people's daily activities as a result of demanding lifestyle for a healthier life as demanded. This awareness exists in certain groups of population. The business position of P.T. SA is a sufficiently fairly good because the company has captive market namely the state-owned hospital and private hospital in the country. According the BPOM that national pharmaceutical sales as shown are as the following table.

 

National Market Trend of Drugs, 2001-2014* (Billion Rupiah)

 

Year

Total Market

Ethical Drugs

Generic Drugs

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014*

12.850

15.483

17.458

20.872

23.629

23.173

25.600

29.981

33.965

37.531

43.081

45.235

47.949

51.305

  7.891

  9.618

10.829

12.706

14.675

13.834

13.959

16.969

19.225

21.142

23.506

25.281

26.798

28.854

1.547

1.694

1.819

2.136

2.529

2.390

2.295

3,213

3.420

3.610

3.900

4.095

4.349

4.653

 

Until this time P.T. SA has not been registered with Indonesian Stock Exchange, so that they had not obliged to announce their financial statement. The management of P.T. SA is very reclusive towards outsiders and rejected to disclose its financial condition. We observed that total sales turnover of the company in 2012 amounted to Rp. 27.2 billion increased to Rp. 28.8 billion in 2013 rose to Rp. 29.6 billion in 2014 and projected to go on rising by at least 5% in 2015. The operation in 2014 yielded an estimated net profit of at least Rp. 2.1 billion and the company has an estimated total networth of at least Rp. 3.0 billion. So far, we did not heard that the company having been black listed by the Central Bank (Bank Indonesia). The company usually pays its debts punctually to suppliers.

 

The management of P.T. SA is led by Mr. Dr. Handy Gunawan (49) a businessman and professional manager with experience in trading, import and distribution of medial equipment. The company's management is handled by professional staff in the above business. They have wide relations with private businessmen within and outside the country. So far, we did not hear that the management of the company being filed to the district court for detrimental cases or involved in any business malpractices. The company’s litigation record is clean and it has not registered with the black list of Bank of Indonesia. P.T. SURGIKA ALKESINDO is sufficiently fairly good for business cooperation.

 

 

 

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.66.60

UK Pound

1

Rs.102.30

Euro

1

Rs.74.61

 

 

INFORMATION DETAILS

 

Analysis Done by :

DIV

 

 

Report Prepared by :

TPT

 

               

RATING EXPLANATIONS

 

RATING

STATUS

PROPOSED CREDIT LINE

 

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

 

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

 

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

 

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

 

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

 

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

 

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

Credit not recommended

 

--

NB

New Business

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.